

Executive Corridor
 Darlington Memorial Hospital
 Hollyhurst Road
 Darlington
 DL3 6HX
 Switchboard Tel: 01325 38 0100
 Foundation Trust Office: 01325 74 3625
 Corporate Records Office: 01325 74 3700

Request for Information Reference: 04.18.16

Direct line: 01325 743700
 Email: cdda-tr.cddftfoi@nhs.net

Email only

9 May 2018

Freedom of Information Act 2000 – Request for Information

Thank you for your request for information received on 11 April 2018 in relation to the County Durham and Darlington NHS Foundation Trust (Trust). We are dealing with your request under the provisions of the Freedom of Information Act 2000.

You requested information regarding Non-Small Cell Lung Cancer (NSCLC) Patients. Specifically you asked for:

Information relating to NSCLC¹ patients treated² by your Trust in the 3 months, December 2017 to February 2018 inclusive? If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below?

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Patients with NSCLC Stage IIIB/IV (Stage 3b/4) ³		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

¹ ICD10 C33, C34

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

³ TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1
 Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Docetaxel (mono or combination therapy)		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Nivolumab (Opdivo)		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

If your Trust does not treat these cancers and you refer your patients to another Trust, please state to which trust(s) patients are referred:

For the avoidance of doubt, we do not require any information that may identify individual patients, clinicians or pharmacists or that may otherwise be categorized as personal data.

County Durham and Darlington NHS Foundation Trust replies:

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Patients with NSCLC Stage IIIB/IV (Stage 3b/4) ^[3]		Total number NSCLC patients	
		Other (please specify)	41*
		Data not held/accessible	

^[3] TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1
Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV

***These are all patients who have been newly diagnosed (newly diagnosed or MDT reviewed recurrence) during the stated time period with a IIIB/IV NSCLC. Some patients will already have been diagnosed and be established on treatment during this time period. Most chemotherapy / immunotherapy treatment is given locally, however other treatment is given by either South Tees Hospitals NHS Trust or Newcastle Hospitals NHS Trust.**

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Docetaxel (mono or combination therapy)	4	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	0	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Nivolumab (Opdivo)	2	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	34**	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

****These include Pembrolizumab used in the first line setting and second line setting. The other medicines detailed are only commissioned in the second line setting.**

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log. Therefore, a version of our response which will protect your anonymity will be posted on the County Durham and Darlington NHS Foundation Trust website.

If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me on the above telephone number or at the above address.

If you are unhappy with the way your request for information has been handled, you can request a review by writing to:

The Chief Executive
County Durham & Darlington NHS Foundation Trust
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX

If, you remain dissatisfied with the handling of your request or complaint, you have a right to appeal to the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Telephone: 0303 123 1113
Website: www.ico.gov.uk.

There is no charge for making an appeal.

Yours sincerely

Joanna Tyrrell
Freedom of Information Officer